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Abstract: The aim of vaccination is to induce appropriate immunity against pathogens. 
Antibody-mediated immunity is critical for protection against many virus diseases, although 
it is becoming more evident that coordinated, multifunctional immune responses lead to the 
most effective defense. Specific antibody (Ab) isotypes are more efficient at protecting against 
pathogen invasion in different locations in the body. For example, compared to other Ab isotypes, 
immunoglobulin (Ig) A provides more protection at mucosal areas. In this study, we developed 
a cationic lipopolymer (liposome-polyethylene glycol-polyethyleneimine complex [LPPC]) 
  adjuvant that strongly adsorbs antigens or immunomodulators onto its surface to enhance or 
switch immune responses. The results demonstrate that LPPC enhances uptake ability, surface 
marker expression, proinflammatory cytokine release, and antigen presentation in mouse 
  phagocytes. In contrast to Freund’s adjuvant, LPPC preferentially activates   Th1-immunity 
against antigens in vivo. With lipopolysaccharides or CpG oligodeoxynucleotides, LPPC dramati-
cally enhances the IgA or IgG2A proportion of total Ig, even in hosts that have developed Th2 
immunities and high IgG1 serum titers. Taken together, the results demonstrate that the LPPC 
adjuvant not only increases the immunogenicity of antigens but also modulates host immunity 
to produce an appropriate Ab isotype by combining with immunomodulators.
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Introduction
The goal of vaccination is to generate a strong immune response that will provide 
long-term protection against infection. For vaccines that are composed of low immu-
nogenic antigens (such as synthetic peptides or subunit antigens), the addition of an 
appropriate adjuvant is necessary to improve the immune response. An ideal adjuvant 
should enhance the immunogenicity of an antigen, reduce the amount of antigens or the 
number of immunizations needed for protective immunity, increase the biological or 
immunological half-life of the antigen, improve antigen delivery and/or processing in 
the antigen-presenting cells (APCs), and induce the production of immunomodulatory 
cytokines.1,2 The adjuvant categories include mineral salts, tensoactive compounds, 
microorganism-derived adjuvants, emulsions, cytokines, polysaccharides, nucleic 
acid-based adjuvants, and particulate antigen delivery systems.1 To date, research has 
focused on particulate antigen delivery systems in which the particles not only enhance 
the immunogenicity of encapsulated antigens by themselves but also incorporate other 
immunomodulatory molecules such as CpG oligodeoxynucleotides (ODN),2 double 
stranded RNA,3 monophosphoryl lipid A,4 or interleukin (IL)-12,5 which results in a 
dramatic increase in their efficacy and even in the switching of immune pathways.
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Different immune responses have various effects on 
the pathogenesis of different diseases. For example, a Th1 
response efficiently attacks virus-infected cells or tumor 
cells but inhibits the Th2 response to produce a humoral 
immune response (antibody production) and vice versa.6 
Certain intracellular pathogens, such as Mycobacterium 
tuberculosis7 and human papilloma virus,8 polarize host 
immunity toward a Th2 response, which is less effective 
against that pathogen than the Th1 response. In contrast, 
three major autoimmune diseases (rheumatoid arthritis, 
multiple sclerosis, and Type 1 diabetes) are characterized 
by an excessively dominant Th1 response that results in 
harm to the host.9 Therefore, if an adjuvant regulates an 
appropriate immune response, it will protect the host 
from pathogen infection, and it will reduce the autoim-
mune response that includes allergic reactions that can 
damage host tissue. In addition, Th1 or Th2 relative 
cytokines are involved in antibody class switching10 
and antibody class is considered to be important in the 
pathogenesis of diseases. For example, immunoglobulin 
(Ig) E antibodies attach to basophils and mast cells by 
way of their surface IgE rec  eptors.   Subsequent exposure 
to an allergen leads to the activation of the IgE-sensitized 
cells and results in an allergic reaction.11 In contrast, fol-
lowing treatment with an allergen, an increase in serum 
IgG levels (particularly IgG4) will lead to the allergen 
being neutralized and the prevention of IgE cross-
linking by the allergen and the degranulation of mast 
cells.12 In addition, depending on their transporting proper-
ties, IgA or IgG1 antibodies provide increased protection 
at mucosal regions and in infants.13 Thus, if an adjuvant 
can induce an appropriate antibody isotype, it will be more 
efficient at protecting the host from disease.
Many adjuvants are surprisingly potent stimulators of 
humoral and cellular immune responses against a variety 
of antigens.14 In addition, certain molecules can affect the 
signal for isotype switching in B cells. It has been demon-
strated that CpG ODN enhance the production of IgG2a,15 
Escherichia coli lipopolysaccharides (LPS) enhance the 
production of IgA,16 and cathelin-related antimicrobial 
peptide increases the production of IgG1.17 Furthermore, 
Fu-Ling extract enhances IgG and IgA secretions18 and 
ginseng extract promotes the production of IgG1, IgG2a, 
and IgG2b.19 Therefore, the combination of particulate 
antigen delivery systems with these immunomodulators 
may provide therapeutic benefits for the treatment of patho-
logical symptoms that are induced by improper immunity 
in humans.
In this study, we evaluated the immunoregulatory   potential 
of the liposome-polyethylene glycol-  polyethyleneimine-
complex (LPPC) adjuvant. LPPC strongly and quickly adsorbs 
antigens onto its surface to form complexes.20 Unlike other 
adjuvants, LPPC binds but does not encapsulate antigen. 
Therefore, antigens are simply mixed with LPPC before use 
and do not need to be emulsified. In addition, the positively 
charged surface of LPPC may bind substances such as LPS 
or CpG ODN, which specifically enhance the production of 
a specific antibody isotype. Furthermore, the liposomal core 
of LPPC may be an immunomodulator carrier. In conclusion, 
the results demonstrate that the combination of antigen and 
immunomodulator with the LPPC adjuvant strengthens the 
efficacy of a vaccine and can switch an improper immune 
response to an appropriate immune response, thus providing 
a benefit in the treatment of human disease.
Materials and methods
Reagents
The reagents 1,2-dioleoyl-sn-glycero-3-phosphocholine and 
1,2-dilauroyl-sn-glycero-3-phosphocholine were purchased 
from Avanti Polar Lipids (Alabaster, AL). Polyethylene 
glycol (PEG; 8000), polyethyleneimine (PEI; branched, 
MW 25,000), LPS, complete Freund’s adjuvant (CFA), 
incomplete Freund’s adjuvant (IFA), and fluorescein 
isothiocyanate (FITC) were purchased from Sigma-Aldrich 
(St Louis, MO). Bovine serum albumin (BSA) and trypan blue 
were purchased from Invitrogen (Gaithersburg, MD). CpG 
ODNs were purchased from InvivoGen (San Diego, CA). 
FITC-conjugated antimouse major histocompatibility com-
plex (MHC) I mAb, FITC-conjugated antimouse MHC II 
mAb, and FITC-conjugated antimouse CD86 mAb were pur-
chased from Biolegend (San Diego, CA). PBST is p  hosphate-
buffered saline (PBS; pH 7.4) with 0.5% Tween-20.
Cell lines
P338D1 (mouse macrophage-like cell line; ATCC nu  mber: 
CCL-46) and Balb/3T3 (mouse fibroblast cell line; ATCC 
number: CCL-163) cell lines were purchased from BCRC 
(Hsinchu, Taiwan, People’s Republic of China). P338D1 cells 
were maintained in RPMI-1640 medium (Invitrogen), which 
was supplemented with heat-inactivated 10% fetal bovine 
serum (Gibco BRL, Gaithersburg, MD), and 1% penicil-
lin/st  reptomycin/amphotericin (PSA;   Biological industries, 
Beithaemek, Israel) with 5% CO2 at 37°C. Balb/3T3 cells 
were maintained in Dulbecco’s mo  dified Eagle medium 
(Invitrogen), which was supplemented with heat-inactivated 
10% fetal bovine serum and 1% PSA with 5% CO2 at 37°C.
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Protein uptake ability and surface-marker 
expression of P338D1
LPPCs were prepared in accordance with procedures   outlined 
in a previous study;20 the characteristics of LPPC with or 
without materials were analyzed. BSA-FITC (50 µg) was 
used as a fluorescent reporter and was adsorbed with differ-
ent amounts of LPPC. BSA-FITC alone or LPPC-adsorbed 
BSA-FITC were cocultured with 5 × 105 P338D1 cells for 
4 hours. Before analysis, the fl  uorescence of the treated cells 
was monitored by fluorescence-activated cell sorting (FACS; 
Becton Dickinson, San Jose, CA) with or without the addition 
of 100 µl trypan blue.
For the surface marker assay, 50 µg BSA was adsorbed 
on 100 µg LPPC, and the LPPC-BSA or BSA alone was co-
cultured with 5 × 105 P338D1 cells for 24 hours. The treated 
cells were probed with FITC-conjugated antimouse CD86, 
antimouse MHC I, or antimouse MHC II mAbs, and the 
surface fluorescence of the cells was measured using FACS. 
The data were expressed as the fold of fluorescent mean – 
the mean fluorescence intensity of the sample divided by the 
mean fluorescence intensity of the untreated group.
Enhancement of presentation efficiency 
by LPPC
Female Balb/c mice (6 to 8 weeks old) were purchased from 
the National Laboratory Center (Taipei, Taiwan, People’s 
Republic of China) and were housed in a temperature- and 
light-controlled room at the Animal Maintenance Facility 
of National Chiao Tung University. The mice were immu-
nized and boosted on day 1 and day 14, respectively, by the 
subcutaneous (sc) injection of 100 µg BSA that was emul-
sified in 100 µL CFA and in 100 µL IFA. The splenocytes 
of all mice were harvested on day 21. BSA (10 µg), LPPC 
(4 µg), or 4 µg BSA/LPPC complex (10 µg BSA adsorbed 
on 4 µg LPPC) were incubated with 5 × 106 splenocytes 
for 72 hours, and the cytokine concentrations of the culture 
supernatants were analyzed using an ELISA reader (Tecan 
Group Ltd, Männedorf, Switzerland).
Determination of antibody titers in sera
Balb/c mice were divided into seven groups and each group 
was immunized using sc injection with 100 µg HpHsp60 
antigen that was mixed with different adjuvants (100 µL 
CFA, 100 µL PBS, 100 µg LPPC, or 150 µg LPPC) or with 
adjuvant alone (100 µL PBS, 100 µg LPPC, or 150 µg LPPC). 
The mice were boosted 2 weeks after immunization with 
an sc injection of 100 µg HpHsp60 in different   adjuvants 
(100 µL IFA, 100 µL PBS, 100 µg LPPC, or 150 µg LPPC) 
or adjuvant alone (100 µL PBS, 100 µg LPPC, or 150 µg 
LPPC). Starting 1 week after the administration of the 
booster, blood was collected by eye bleeding every 3 days and 
HpHsp60-specific antibodies in the sera were measured. The 
wells of 96-well plates were coated with HpHsp60 proteins 
(100 ng/well) overnight at 4°C. The wells were blocked with 
300 µL PBST plus 2% skim milk (Mediatech, Herndon, 
VA) for 1 hour and were washed once with PBST plus 0.5% 
skim milk. One hundred microliters of serially diluted serum 
samples (1:100 to 1:12,800 in PBS containing 0.5% skim 
milk) was loaded into the wells and incubated for 2 hours. 
After washing three times, 100 µL horseradish peroxidase-
conjugated antimouse Ig antibody (1:10000 dilution; Sigma 
Aldrich) was added to each well and incubated for 1 hour. 
The plates were washed three times and 100 µL of tetram-
ethylbenzidine substrate (Pierce, Rockford, IL) was added to 
each well. After incubation for 20 minutes, the reaction was 
stopped using 100 µL 1 N HCl, and the optical density was 
measured at 450 nm using the ELISA reader.
To determine the effect of immunomodulators on anti-
HpHsp60 titers, CpG ODN and LPS were adsorbed by 
LPPC. LPPC (150 µg) was incubated with 1 µg CpG ODN, 
1 µg LPS or 2 µg LPS for 30 minutes and was centrifuged 
at 5900 × g for 5 minutes; the pellet was then resuspended 
in 100 µL PBS. Immuno-LPPC was used for immunizations 
by sc injection as described above. Blood was collected by 
eye bleeding every 3 days. HpHsp60-specific antibodies in 
the sera were measured as described.
Determination of anti-HpHsp60 isotype 
in sera
The mice were divided into seven groups and were i  mmunized 
and boosted as described above. Blood was collected by eye 
bleeding, and the isotypes of HpHsp60-specific antibodies in 
the sera were determined at 21 days. The sera (1:800 dilution) 
were evaluated using horseradish peroxidase-conjugated 
antimouse Ig antibodies (total Ig, IgG1, IgG2a, IgG2b, IgA, 
and IgM; Acris, Herford, Germany). Similarly, the antibody 
isotypes in the sera of the mice immunized with LPPC-CpG 
ODN or -LPS were measured.
To determine if LPPC adsorbed with CpG ODN or LPS 
could change the original immune responses in vivo, mice 
were preimmunized with Freund’s adjuvant containing 
HpHsp60. At day 21 (the third week), the mice were immu-
nized with LPPC alone or LPPC containing CpG ODN or 
LPS. Blood was collected once a week for 7 weeks (49 days) 
and the isotypes of the anti-HpHsp60 antibodies in the sera 
were evaluated.
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ELISPOT
Mice were immunized and boosted with HpHsp60 alone 
or HpHsp60 combined with adjuvant (Freund’s adjuvant, 
100 µg LPPC, or 150 µg LPPC) as described above. 
Sp  lenocytes were collected from the treated mice 21 days 
after immunization, and the number of cells expressing 
IL-4 or IFN-γ was monitored using a U-CyTech BV mouse 
ELISpot kit (IFN-γ or IL-4; U-CyTech, Yalelaan, The 
Netherlands) in accordance with the manufacturer’s standard 
protocol. The spots in the wells were visualized and counted 
using an inverted microscope (Olympus, Tokyo, Japan).
Cytokine ELISA
Peripheral blood mononuclear cells (PBMCs) (105 cells per 
well) or splenocytes (2.5 × 105 cells per well) were dispensed 
into 96-well culture plates and were treated with 1 µg LPPC. 
The supernatants were collected at 72 hours and were frozen 
at −80°C. Supernatant concentrations of TNF-α, IL-1β, IL-4, 
IL-6, IL-8, IL-10, IL-2, and IFN-γ cytokines were measured 
by ELISA (ELISA kit; R&D Systems, Minneapolis, MN).
The mice were divided into seven groups and were immu-
nized and boosted as described above. Splenocytes (2.5 × 105 
cells per well in a 96-well plate) from treated mice were 
pulsed with HpHsp60 antigen (1 µg/mL) for 72 hours. The 
supernatants were analyzed for cytokines (TNF-α, IL-1β, 
IL-4, IL-10, IL-2, and IFN-γ using ELISA (R&D Systems). 
To examine the changes in the cytokine profiles of mice 
that were immunized with LPPC-CpG ODN or LPPC-LPS, 
splenocytes (2.5 × 105 cells per well in a 96-well plate) from 
the mice treated with HpHsp60 combined with Freund’s 
adjuvant, LPPC, LPPC-LPS, or LPPC-CpG were pulsed with 
HpHsp60 antigen (1 µg/mL) for 72 hours. The supernatants 
were collected and were analyzed for cytokines (IL-4, IL-5, 
TGF-β, and IFN-γ) using ELISA (R&D Systems).
The effect of LPPC adjuvant  
on cytotoxicity
Balb/3T3 cells were transfected with pCJ-HpHsp60 or 
pCJ-Helicobacter pylori urease B (HpUreaseB) (provided 
by Dr Wu, National Taiwan Ocean University) and expressed 
heat shock protein 60 or HpUreaseB, respectively. The 
transfected Balb/3T3 cells were plated (1 × 104 cells/well in 
a 96-well plate) and were incubated overnight. Splenocytes 
that were obtained from the immunized mice were added to 
the wells as effector cells at an effector:target cell ratio of 
100:1, 50:1, 25:1, and 12.5:1. After incubation for 72 hours, 
the supernatants were removed, the wells were washed six 
times with PBS, and the cell viabilities were determined 
by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide assay (Sigma-Aldrich). The lysis percentage was 
calculated using the following equation: the survival rate of 
the nontreated group (100%) minus the survival rate of the 
treated individual group.
Statistical analysis
All experiments were carried out independently and in 
triplicate. Standard deviations (SDs) of the mean were 
calculate, and data were analyzed using the SAS statistical 
software package (SAS Institute, Inc, Cary, NC). The results 
were expressed as the mean ± SD. Differences in mean values 
were evaluated by a one-way analysis of variance. The level 
of significance considered was P , 0.05.
Results
The effects of LPPC on antigen 
presentation
To evaluate the effect of the adjuvant LPPC on the uptake 
ability, surface marker expression and presentation efficiency 
of antigen presenting cells were analyzed. First, the ability to 
facilitate antigen uptake in macrophages by phagocytosis was 
determined. BSA-FITC (green fluorescence) was used as a 
reporter protein. Figure 1 indicates that BSA-FITC that is 
adsorbed on LPPC increased the fluorescence of P338D1 cells 
compared with BSA-FITC alone. However, it could not be 
distinguished whether the fluorescence was intracellular or 
present on the surface of the cells. Therefore, trypan blue, an 
agent that quenches the green fluorescence of FITC, was used 
to verify the location of the fluorescence. Because trypan blue 
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Figure  1  The  effects  of  LPPC  on  the  antigen  uptake  ability  of  P338D1  cells. 
The fluorescent protein (BSA-FITC) was absorbed on LPPC as a reporter antigen 
and was incubated with P338D1 cells. With (open bar) or without (closed bar) the 
addition of trypan blue, the fluorescence was analyzed using FACS. The cells with a 
fluorescence higher than that of the untreated cells were counted as positive cells. 
The fluorescent rate is presented as follows: (the number of positive cells divided by 
the number of untreated cells) multiplied by 100%.
Abbreviations:  BSA,  bovine  serum  albumin;  FITC,  fluorescein  Isothiocyanate; 
LPPC, liposome-polyethylene glycol (PEG)-polyethyleneimine (PEI) complex.
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cannot cross the membrane of living cells, it can only per-
form its quenching activity extracellularly. The results show 
that treatment with trypan blue did not completely block the 
increases in fluorescence observed after treatment with LPPC/
BSA-FITC complexes, indicating that LPPC facilitates the 
uptake of BSA-FITC by P338D1 cells (Figure 1).
APC maturation is associated with the increased expres-
sion of several surface markers that lead to the efficient 
presentation of antigen. The influence of LPPC on the 
expression of molecules involved in antigen presentation was 
determined. For 12 hours following treatment, LPPCs dem-
onstrated their ability to enhance the expression of MHC I, 
MHC II, and CD86 on the cell surface. Moreover, LPPC 
complexed with the BSA antigen increased the expression of 
these molecules compared with LPPC alone (Figure 2).
Next, the effect of LPPC on the presentation of specific 
antigens was verified. Splenocytes from mice immunized or 
not immunized with BSA were examined for cytokine expres-
sion following the addition of different reagents. The results 
revealed that neither BSA alone nor the BSA/LPPC complex 
can induce significant cytokine expression in splenocytes 
derived from mice not immunized with BSA; however, both 
BSA alone and the BSA/LPPC complex induce significant 
cytokine expression in splenocytes from mice previously 
immunized with BSA. In addition, the BSA/LPPC complex 
induced the release of higher levels of Th1-cytokines (IL-2 
and IFN-γ) and Th2-cytokines (IL-4 and IL-10) compared to 
BSA alone (Figure 3). The release of specific cytokines from 
T cells requires the presentation of antigen from the antigen-
presenting cell. Therefore, LPPC facilitates antigen presenta-
tion to allow the more efficient activation of T cells.
Finally, we evaluated whether LPPC alone affects 
cytokine expression. Table 1 shows that LPPC significantly 
increased the secretion of the proinflammatory cytokines 
TNF-α, IL-1β, IL-6, and IL-8. However, LPPC alone did not 
stimulate the expression of Th1-cytokines (IL-2 and IFN-γ) 
and Th2-cytokines (IL-4 and IL-10).
The adjuvant effect of LPPC  
for the production of antibody in vivo
To evaluate the efficiency of LPPC as an effective adjuvant 
in vivo, we utilized HpHsp60 as an antigen and compared it 
with the traditional Freund’s adjuvant (CFA and IFA). After 
completion of the immunization protocol, the titers of anti-
HpHsp60 antibodies in the sera were measured. Figure 4A 
shows that 150 µg LPPC adsorbed with HpHsp60 induced 
titers of specific anti-HpHsp60 antibodies that were similar 
to those induced by Freund’s adjuvant. However, 100 µg 
LPPC adsorbed with HpHsp60 produced lower titers of anti-
HpHsp60 antibodies compared with Freund’s adjuvant.
Although total antibody production in vivo by LPPC 
adjuvant was similar to Freund’s adjuvant, we were interested 
to determine whether the two adjuvants induced different 
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Figure 2 The surface maker expression of mouse phagocytes after LPPC treatment. 
The surface marker expression of P338D1 cells was analyzed by FACS following 
the incubation of BSA antigen alone or BSA antigen in combination with LPPC. The 
fold of fluorescence mean was evaluated using the following equation: the mean 
fluorescence intensity of the sample divided by the mean fluorescence intensity of 
the untreated group.
Note: A significant difference between BSA antigen in combination with LPPC and 
the BSA alone group is indicated by *P , 0.05 and **P , 0.01.
Abbreviations: MHC, major histocompatibility complex; PBS, phosphate-buffered 
saline;  BSA,  bovine  serum  albumin,  LPPC,  liposome-polyethylene  glycol  (PEG)-
polyethyleneimine (PEI) complex.
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antibody isotypes. Therefore, we analyzed the percentages of 
antibody isotypes that were produced by the two adjuvants. 
The results demonstrate that the major antibody isotype 
induced by Freund’s adjuvant was IgG1 (Figure 4B). In 
contrast, the major antibody isotype induced by both doses 
of LPPC was IgG2a. With the exception of IgG1 and IgG2a, 
the other antibody isotypes induced by Freund’s adjuvant 
or LPPC were similar (Figure 4B). These results indicate 
that Freund’s adjuvant enhances the production of antibody 
through the Th2 pathway, whereas LPPC enhances antibody 
production through the Th1 pathway.
Isotype or antibody switching is dependent on the types 
of cytokines that are produced following stimulation with 
antigens. To prove that the two adjuvants induce different 
immune pathways, we examined the types of cytokines that 
were induced by antigen stimulation following immunization. 
The cytokines released from splenocytes that were immunized 
with Freund’s adjuvant were Th2 cytokines (IL-4 and 
IL-10) and IL-1β and were different to the Th1 cytokines 
(IL-2, INF-γ and TNF-α) that were released from spleno-
cytes immunized with LPPC (Figure 5). Figure 6 indicates 
that antigen immunization with LPPC leads to an increase in 
the number of INF-γ-expressing T cells (Th1 cells), whereas 
immunization with Freund’s adjuvant leads to an increase in 
the number of IL-4-expressing T cells (Th2 cells). The induc-
tion of the Th1 pathway is a cytotoxic immune response, and 
induction of the Th2 pathway is a humoral immune response. 
Therefore, whether or not LPPC also enhances cytotoxic activ-
ity was examined. In accordance with previous results, a cell-
mediated immune response (CTL) assay revealed that both 
doses of LPPC increased the activity of Hsp60-specific CTL 
against cells transfected with a transgene encoding Hsp60, 
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Figure 3 The effects of LPPC on the presentation efficiency of mouse antigen presenting cells. After incubation of splenocytes from naive mice (solid columns) or   
BSA-immunized mice (open columns) with LPPC complex, the concentration of the cytokines (A) interleukin (IL)-2, (B) IL-4, (C) interferon-gamma (IFN-γ ), and (D) IL-10 in 
the supernatants was determined by ELISA.
Notes: Data are expressed as the mean ± standard deviation, and experiments were carried out in duplicate (n = 6). A significant difference compared to the BSA group is 
indicated by *P , 0.05 and **P , 0.01.
Abbreviations: PBS, phosphate-buffered saline; BSA, bovine serum albumin; LPPC, liposome-polyethylene glycol (PEG)-polyethyleneimine (PEI) complex.
Table 1 The effects of LPPC on the expressions of cytokines in PBMCs or mouse splenocytes
Cytokine TNF-α IL-1β IL-6 IL-8 IL-2 IFN-γ IL-4 IL-10
immune cells
PBMC (±LPPC) −   61.6 ± 12   8.7 ± 5.3   71.1 ± 19.2 67.5 ± 26.7 30.9 ± 7.3 0.5 ± 1.9 21.2 ± 7.6 38.5 ± 8.0
+ 196.4 ± 32.9* 29.8 ± 9.0* 105.7 ± 17.2* 90.1 ± 14.5* 29.9 ± 7.4 1.0 ± 3.0 24.6 ± 9.4 30.5 ± 10.4
Splenocyte (±LPPC) −   16.4 ± 5.2 18.3 ± 6.9   34.9 ± 6.8 11.9 ± 3.6 13.6 ± 5.6 2.9 ± 5.3 11.4 ± 4.2 17.9 ± 5.8
+   69.9 ± 9.2* 32.7 ± 11.5*   44.5 ± 8.6* 19.8 ± 4.8* 13.6 ± 4.3 3.7+ ± 4.3 14.5 ± 4.5 19.5 ± 7.6
Notes: This table summarizes the effects of LPPC on cytokine release from human PBMCs or mouse splenocytes. The secretion of tumor necrosis factor-alpha (TNF-α), 
interleukin (IL)-1β, IL-6, IL-8, IL-2, IL-4, IL-10, and interferon-gamma (IFN-γ ) was determined. *P , 0.05.
Abbreviations: PBMC, peripheral blood mononuclear cell; LPPC, liposome-polyethylene glycol (PEG)-polyethyleneimine (PEI) complex.
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but not against cells expressing Urease B; this is in contrast 
to what was observed using Freund’s adjuvant (Figure 7).
The ability of LPPC to regulate the 
production of different antibody isotypes
According to the results, certain reagents enhance the produc-
tion of specific antibody isotypes. First, the ability of E. coli 
LPS to raise IgA production following adsorption onto LPPC 
was examined. CpG oligonucleotides were also examined 
for their ability to increase IgG2a production. LPPC easily 
adsorbs LPS or CpG oligonucleotides (results not shown). 
Figure 8A shows that both LPS and CpG increase the total 
titer of specific antibodies induced by LPPC. Following iso-
typing, the results indicate that LPS significantly increases 
the production of IgA and CpG significantly increases the 
production of IgG2a (Figure 8B). Consistent with a published 
study,2 CpG facilitates the ability of LPPC to increase the 
activity of CTL against cells expressing the specific antigen 
Hsp60 (HpHsp60) but not against cells expressing Urease B 
(Figure 9), whereas LPS has no effect on the ability of LPPC to 
increase specific CTL (Figure 9). Antibody isotype switching 
is dependent on certain cytokines, such as IL-4, IL-5, IFN-γ, 
and TGF-β. The cytokine assays indicated the following: 
immunization with Freund’s adjuvant resulted in the highest 
expression of IL-4; LPS in combination with LPPC increased 
the expression of IL-4, IL-5, and TGF-β; and CpG ODN in 
combination with LPPC increased the production of INF-γ 
(Figure 10).
Finally, we examined if the “LPPC-based adjuvant” 
can switch the antibody isotype in animals that have been 
immunized. Interestingly, Figure 6 shows that the boost with 
Hsp60 and LPS antigens increased IgA and IgG1 production 
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after 7 days compared with the boost with Hsp60 alone. CpG 
ODN enhanced IgG2a production at 7 days, but at 28 days, 
the IgG1 titer in the sera was decreased (Figure 11). Our 
results have revealed that LPPC easily adsorbs antigen and 
immunomodulatory molecules, and is a vaccine that pos-
sesses dramatic properties that can control the production 
of antibody isotypes.
Discussion
In this study, we describe an interesting adjuvant, LPPC, 
which easily and strongly adsorbs antigen to form a 
complex. Previously, it was shown that LPPC strongly binds 
DNA and many kinds of proteins, and that these adsorbed 
substances cannot be replaced by the addition of other 
proteins.20 Acc  ordingly, antigens bind tightly to LPPC to 
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form a stable complex. LPPC, similar to Freund’s adjuvant, 
enhances the production of specific anti-antigen antibodies 
(Figure 4A). It is obvious from our results that LPPC pref-
erentially induces Th1 responses including increases in the 
levels of IgG2a (Figure 4B), IFN-γ release (Figure 5), and CTL 
(Figure 7), and compared to Freund’s adjuvant, LPPC nega-
tively regulates Th2 responses. Interestingly, LPPC can easily 
combine with immunomodulators to polarize the immune 
response. When complexed with LPS, LPPC increases the 
production of IgA in sera without decreasing the production 
of IgG2a. This indicates that the addition of LPS to LPPC may 
increase the expression of IgA in mucosal areas and still allow 
a strong CTL in a host in which such an immune response is 
considered a good immunity and is induced by a vaccine that 
provides protection against viral infections via the respiratory 
or digestive tracts. A study has shown that CpG ODN are 
good adjuvants that induce a Th1 response,2 including a sig-
nificant increase in Th1-biased cytokine and chemokine gene 
transcripts and the regulation of co-stimulatory and surface 
marker molecule expression.2 Compared with LPPC alone, 
LPPC in combination with CpG ODN not only significantly 
facilitates LPPC’s ability to produce higher levels of IgG2a, 
but also dramatically raises CTL activity, which suggests 
that it may be a good therapeutic vaccine against cancer. In 
addition, the increase of LPPC induces higher Ab response 
to Hsp60, which might be explained by an improved binding 
and stability of the adsorbed Ab. Furthermore, combining 
LPPC with immunomodulators can induce antibody isotype 
switching (Figure 11), suggesting that LPPC can be used as an 
efficient and flexible vector for the development of vaccines 
and to facilitate the switch from an improper immunity to an 
immunity that is appropriate to fight disease.
To date, many biomaterials have been developed as vectors 
that enhance the immunogenicity of antigens. However, the 
immunogenicity of these adjuvants is often considered insuf-
ficient to activate APCs and efficiently eliminate the pathogen. 
Therefore, to achieve a higher immunogenicity or to induce 
proper immunity, these systems have been modified by incor-
porating immunomodulators. For example, poly(D, L-lactide-
co-glycolide), a copolymer codelivering antigen, enhances the 
humoral immune response (Th2-cell dependent) by increasing 
phagocytic activity,21–23 whereas monophosphory lipid A, 
a Toll-like receptor (TLR) 4 agonist, significantly increases 
this system’s ability to induce a cytotoxic T cell response.4 In 
addition, the adjuvant chitosan has been developed as a vac-
cine24 due to its ability to increase macrophage uptake when 
it is combined with mannose for intranasal immunizations25 
or when it is combined with IL-12 to improve Th1 cytokine 
release.5 Cationic liposomal vectors are also considered good 
adjuvants that enhance Th1 immune responses. However, the 
capabilities of some of these adjuvants were also increased 
by incorporating immunomodulators, such as CpG ODN,2,26 
LPS,27 and IFN-γ.28 Some immunomodulators, because they 
are natural TLR ligands, activate immunity by engaging 
with TLRs on/in APCs.29 Other immunomodulators include 
cytokines, that are proposed to activate a Th1 response such as 
IL-2, IFN-γ, and IL-12, and other immunomodulators that are 
considered to be Th2 activators, such as IL-4, IL-10, and IL-5.9 
Certain compounds that are derived from the extracts 
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of herbs, such as saponins30 and   Fu-Ling, are considered good 
immunomodulators.18 Studies have combined particulate 
antigen delivery systems with immunomodulators to create an 
efficient adjuvant that strongly induces appropriate immune 
responses against disease.2–5 In addition to the adsorption of 
protein antigens and modulators such as CpG ODN or LPS, 
our studies also reveal that LPPC easily incorporates hydro-
phobic compounds, such as 3,3-Dioctadecyloxacarbocyanine 
perchlorate dye20 or curcumin,31 following a short incubation 
period of blank LPPC with the compound. This indicates 
LPPC is a useful adjuvant and is a convenient platform for 
examining combinations of antigens and immunomodulators 
that can best induce proper immunity.
In contrast, antibody isotype switching has been inves-
tigated as a therapy for some diseases. In this phenomenon, 
specific cytokines are considered critical factors in host 
switching of antibody isotypes. Chow et al demonstrated that 
the incorporation of a cytokine gene (IL-12, IFN-γ, and IL-4) 
in a DNA vaccine formulation influences the differentiation 
of Th cells and the nature of an immune response and may, 
therefore, provide a strategy to improve the prophylactic and 
therapeutic efficacy of the vaccine.32 Furthermore, IL-21 
regulates IgE-production in B cells in vivo.33 Moreover, 
Mueller et al utilized recombinant adeno-associated virus 
vectors encoding IL-13 and IL-17ε soluble receptors to 
neutralize IL-13 and IL-17 to modulate IgE expression.34
This immunostimulatory activity of LPPC may be due 
to an increase in the antigen-presenting activity of APC. 
It has been established that the activation of T cells is 
closely associated with the presentation of APC, which 
results in a humoral response of varying strengths. 
T cells recognize processed antigen that is presented in 
MHC I or MHC II molecules but not the intact antigen 
itself. Therefore, additional antigens must be presented on 
MHC I or MHC II molecules on APCs to induce cytokine 
expression in activating T cells. Figure 3 indicates that 
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compared with antigen alone, LPPC increases the expression 
of Th1 (IL-2 and IFN-γ) and Th2 (IL-4 and IL-10) cytok-
ines in T cells, suggesting that LPPC has an increased 
ability to facilitate BSA antigen presentation compared 
with BSA alone. This increase in presentation may result 
from facilitating antigen uptake (Figure 1), increasing the 
expression of presenting molecules (MHC I, MHC II, and 
CD86; Figure 2) and inducing the expression of proinflam-
matory cytokines, including TNF-α, IL-1β, IL-6, and IL-8 
(Table 1). We propose that these properties are associated 
with the PEI component of LPPC. PEI activates Th1 and 
Th2 gene expression in murine splenocytes.35 Although 
only a few PEI molecules are incorporated into LPPC 
(1 µg/100 µg LPPC), they contribute to the positive charge 
on the surface zeta potential of LPPC.20 As a cationic 
liposome, the positive charge of PEI aids particle uptake by 
the electronic interaction between LPPC and APCs.36,37
Compared with Freund’s adjuvant, antigen   immunization 
with LPPC enhances the production of IgG2a but not IgG1 
(Figure 4B), triggers increased expression of Th1 cytokines 
(IL-2, IFN-γ, and TNF-α; Figure 5), and increases CTL activ-
ity (Figure 7). Therefore, LPPC activates the Th1 pathway. 
Figure 6 demonstrates that immunization with LPPC induces 
an increase in Th1 cells, whereas immunization with Freund’s 
adjuvant induces an increase in Th2 cells in mice. An endog-
enous antigen (eg, an intracellular virus antigen), presented in 
MHC I, preferentially promotes the Th1 immune response.38 
Our unpublished results demonstrate that LPPC adsorbs trans-
genes and delivers them into cells where they are expressed. 
The transfection activity of LPPC is associated with PEI, which 
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transfects transgenes into cells using the endosome pathway39 
and releases the transfected DNA from the endosome into 
cytosol via the hydrogen sponge effect.40 Furthermore, PEI 
delivers proteins into cells and facilitates protein release from 
the endosome toward the MHC I pathway.41–43 Therefore, we 
propose that LPPC delivers proteins into cells resulting in the 
exogenous antigen becoming an endogenous antigen that is 
processed and presented on MHC I molecules.
Conclusion
In this study, we demonstrated that LPPC is an adjuvant that 
enhances mouse immunity against antigens and specifically 
increases Th1-related immune responses. In addition, LPPC 
in combination with immunomodulators promotes antibody 
isotype switching. Therefore, LPPC may have clinical appli-
cations for the induction of appropriate immunity against 
pathogens and disease.
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